NASDAQ:AVDL

Avadel Pharmaceuticals Stock Forecast, Price & News

$6.67

+0.06 (+0.91 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.39

Now: $6.67▼

$6.70

50-Day Range

$6.29

MA: $6.96▼

$7.95

52-Week Range

$4.00

Now: $6.67▼

$13.49

Volume270,792 shs

Average Volume442,183 shs

Market Capitalization$388.66 million

P/E Ratio33.35

Dividend YieldN/A

Beta1.55

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

MarketRank^™

Overall MarketRank^™

1.35 out of 5 stars

Medical Sector

544th out of 1,558 stocks

Pharmaceutical Preparations Industry

276th out of 638 stocks

3.5 Analyst's Opinion

Consensus Rating
Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.56, Avadel Pharmaceuticals has a forecasted upside of 148.3% from its current price of $6.67.
Amount of Analyst Coverage
Avadel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Avadel Pharmaceuticals has received 286 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Avadel Pharmaceuticals has received 302 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Avadel Pharmaceuticals has received 51.36% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote “Outperform” if you believe AVDL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Avadel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Avadel Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.41% of the stock of Avadel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
53.78% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Avadel Pharmaceuticals are expected to decrease in the coming year, from ($0.69) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avadel Pharmaceuticals is 33.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.50.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avadel Pharmaceuticals is 33.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.91.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AVDL

Previous Symbol

CUSIPN/A

CIK1012477

Webwww.avadel.com

Phone011-1-485-1200

Employees50

Debt

Debt-to-Equity Ratio0.74

Current Ratio12.24

Quick Ratio12.24

Price-To-Earnings

Trailing P/E Ratio33.35

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$59.22 million

Price / Sales6.56

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.78) per share

Price / Book-8.55

Profitability

EPS (Most Recent Fiscal Year)($0.89)

Net Income$-33,230,000.00

Net Margins38.70%

Return on Equity-33.91%

Return on Assets-11.75%

Miscellaneous

Outstanding Shares58,270,000

Market Cap$388.66 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$6.67

+0.06 (+0.91 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

How has Avadel Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVDL stock has decreased by 16.5% and is now trading at $6.67.
View which stocks have been most impacted by COVID-19.

Is Avadel Pharmaceuticals a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avadel Pharmaceuticals stock.
View analyst ratings for Avadel Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Avadel Pharmaceuticals?

Wall Street analysts have given Avadel Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avadel Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Avadel Pharmaceuticals.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its earnings results on Saturday, November, 14th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.05. Avadel Pharmaceuticals had a negative return on equity of 33.91% and a net margin of 38.70%.
View Avadel Pharmaceuticals' earnings history.

What price target have analysts set for AVDL?

9 analysts have issued 1 year price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $13.50 to $22.00. On average, they expect Avadel Pharmaceuticals' share price to reach $16.56 in the next twelve months. This suggests a possible upside of 148.3% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Avadel Pharmaceuticals' key competitors?

Some companies that are related to Avadel Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Constellation Pharmaceuticals (CNST), Repare Therapeutics (RPTX), Rhythm Pharmaceuticals (RYTM), Zealand Pharma A/S (ZEAL), COMPASS Pathways (CMPS), Keros Therapeutics (KROS), Trillium Therapeutics (TRIL), Arcturus Therapeutics (ARCT), Amneal Pharmaceuticals (AMRX), ImmunoGen (IMGN), Travere Therapeutics (RTRX), Cytokinetics (CYTK), Dyne Therapeutics (DYN) and Mersana Therapeutics (MRSN).
View all of AVDL's competitors.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold Holdings Limited (CGH.L) (CGH), Associated British Foods plc (ABF.L) (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:

Mr. Gregory J. Divis Jr., CEO & Director (Age 54, Pay $917.95k)
Mr. Thomas S. McHugh, Sr. VP & CFO (Age 56, Pay $404.26k)
Dr. Jordan S. Dubow M.D., Consultant (Age 43, Pay $567.63k)
Mr. Gregory J. Davis, VP of Corp. and Bus. Devel. (Age 56)
Mr. Mark W. Elrod, VP of Sales
Mr. Christian Kalita Pharm.D, Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
Mr. Steven G. Sullivan, VP of Sales & Marketing and Head of Commercial Operations (Age 56)
Dr. Jason M. Vaughn, Sr. VP of Technical Operations
Mr. Jerad G. Seurer, VP of Legal Affairs & Corp. Sec.

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $6.67.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $388.66 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 50 workers across the globe.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is www.avadel.com.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at 011-1-485-1200 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here